Venture investment in health care cratered in 2012. While others cut back, SR One charged ahead.
The venture arm of GlaxoSmithKline formed in 1985 and has steadily invested $30 million to $50 million annually. Seeing strong prospects at a time when many conventional venture firms had to sit it out, SR One invested more than $50 million last year, making eight new deals and eight follow-on investments, said Jens Eckstein, its president.
To read the full, original article click on this link: SR One Steady Amid Health-Care Slump - Venture Capital Dispatch - WSJ
